United States · Financial press · Investor's Business Daily
Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development
Shares of Nurix Therapeutics crashed Wednesday after Sanofi unexpectedly scrapped an experimental eczema drug that two were codeveloping. The post Nurix, Sanofi Diverge — And One…
Read the full article on Investor's Business Daily Sign in to saveMarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.investors.com)